Company Information
CIN
Status
Date of Incorporation
29 November 1984
State / ROC
Hyderabad / ROC Hyderabad
Last Balance Sheet
31 March 2023
Last Annual Meeting
31 July 2023
Paid Up Capital
487,025,270
Authorised Capital
1,250,000,000
Directors
Sarada Kalyani Bhagawati
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Rajiv Krishan Luthra
Director/Designated Partner
over 10 years ago
over 10 years ago
Mohit Saraf
Director/Designated Partner
over 10 years ago
over 10 years ago
Nagaraj Goud Bodige
Non Individual Subscriber
over 14 years ago
over 14 years ago
Jagdish Viswanath Dore
Managing Director
over 17 years ago
over 17 years ago
Prasad Nimmagadda
Director
almost 19 years ago
almost 19 years ago
Arun Duggal
Director
almost 21 years ago
almost 21 years ago
Past Directors
Rakesh Bamzai
Additional Director
about 11 years ago
about 11 years ago
Hari Babu Bodepudi
Managing Director
over 13 years ago
over 13 years ago
Susanto Banerjee
Whole Time Director
about 14 years ago
about 14 years ago
Seshan Srinivasan
Additional Director
almost 17 years ago
almost 17 years ago
Rajiv Malik
Managing Director
almost 19 years ago
almost 19 years ago
Kugalur Ramsesha Venkata Subrahmanian
Director
over 22 years ago
over 22 years ago
Chunduri Ramakrishna
Director
almost 25 years ago
almost 25 years ago
Patents
1. Crystalline Atropine Sulfate
ABSTRACT:
The invention relates to a ready to use, non-aqueous pharmaceutical compositions comprising voriconazole or its pharmaceutically acceptable salts thereof. The invention also relates to a process for preparation of a ready to use, non-aqueous pharmaceutical composition comprising voriconazole a pharmaceuti...
The present invention relates to a process for the preparation of pure anhydrous crystalline Valacyclovir hydrochloride polymorphic form II
PROCESS FOR THE PREPARATION OF TADALAFIL
The present invention relates to an improved process for the preparation of tadalafil.
The present disclosure provides process for the purification of 9-{(R)-2-[((R,S)-{[(S)-l-(isopropoxycarbonyl)ethyl]amino} phenoxyphosphinyl) methoxy] propyl}adenine using acids to give enantiomerically pure tenofovir alafenamide.
The present invention relates to an improved process for the preparation of Vilazodone or its pharmaceutically acceptable salts comprises, reacting 5-{4-[4-(5-CyanorlH-indol-3-yl)-butyl]-piperazin-l-yl}-benzofuran-2-carboxylic acid alkyl ester with ammonia source.
The present disclosure provides a process for the preparation of 2-(2-amino propan-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxamide by debenzylation of benzyl(2-{4-[(4-fluorobenzyl)carbamoyl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl}propan-2-yl)carbamate. This process ...
"PROCESS FOR THE PREPARATION OF FLUTICASONE PROPIONATE"
The present disclosure relates to an improved process for the preparation of fluticasone propionate.
The present disclosure relates to novel crystalline dolutegravir sodium Form-M2, Form-M3, Form-M4 and process for the preparation thereof.
“IMPROVED PROCESS FOR THE PREPARATION OF RITONAVIR”
The present disclosure provides an improved process for the preparation of ritonavir form I.
The present disclosure provides anamorphous solid dispersion of palbociclib and a process for the preparation thereof. The solid dispersions disclosed herein may be useful for pharmaceutical compositions or dosage forms.
PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR
Processes for the preparation of dolutegravir and pharmaceutically acceptable salts utilizing alkenylamine are disclosed. Intermediates in those synthetic schemes are also disclosed.
NOVEL CRYSTALLINE FORMS OF VORTIOXETINE, PREMIXES, AND PROCESSES FOR THE PREPARATION THEREOF
Crystalline forms of vortioxetine hydrobromide, designated as form-M1, form-M2, form-M3, and form-M4are disclosed herein.The present disclosure also provides apharmaceutical premix of crystalline form-M2 of vortioxetine hyd...
PROCESSES FOR THE PREPARATION OF VORTIOXETINE HYDROBROMIDE
The present invention relates to a process for the preparation of vortioxetine and its pharmaceutically acceptable salts.
The amorphous form of trisodium sacubitril valsartan and methods for the preparation thereof are disclosed herein.
The present disclosure relates to crystalline dolutegravir sodium Form-M1, which is an N-methyl-2-pyrrolidone solvate, and a process for the preparation thereof.
PROCESS FOR THE PREPARATION OF IBRUTINIB
A processes for the preparation of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one (ibrutinib). The disclosed process may be useful for preparing ibrutinib that may be included in pharmaceutical dosage forms.
...
The present invention relates to an improved process for the preparation of Azahexane derivatives.
The present disclosure provides a process for the preparation a premix of raltegravir potassium form 3 with excipients. This premix may be used in the manufacture of pharmaceutical formulations containing raltegravir.
ABSTRACT
“Process for the preparation of Efavirenz monohydrate”
The present invention relates to process for the preparation of crystalline efavirenz monohydrate comprising dissolving efavirenz in formic acid and adding the obtained solution to water to get crystalline efavirenz monohydrate.
Cobicistat-silicon dioxide particles and pharmaceutical compositions containing the same. The compositions and processes disclosed herein provide cobicistat-silicon dioxide particles that possess satisfactory processability for incorporation into a pharmaceutical composition.
NOVEL PROCESS FOR THE PREPARATION OF SACUBITRIL AND ITS INTERMEDIATES
A process for the preparation of sacubitril and its intermediates is disclosed. By practicing the methods disclosed herein, a solid form of sacubitril may be generated. A crystalline form of sacubitril is also disclosed.
...
AMORPHOUS APREMILAST, PREMIXES THEREOF, AND NOVEL CRYSTALLINE FORMS OF APREMILAST
A process for the preparation of amorphous apremilast. A premix of amorphous apremilast with pharmaceutically acceptable excipients and process for the preparation thereof are also disclosed. Processes for the preparation of aniso...
Processes for the preparation of amorphous idelalisib are provided. Processes for the preparation of a premix of amorphous idelalisib are also provided.
The present invention relates to an improved process for the preparation cis-nucleoside derivative of formula-1 involving chlorination of the compound of formula-2 followed by reaction with compound of formula-3 in presence of a base to get compound of formula-4, reacting compound of formula-4 with an alkyl halide (...
The present invention relates to a novel process for the synthesis of Enfuvirtide or pharmaceutically acceptable salts by- using a hybrid approach. The fragments are synthesized by solid phase synthesis approach and the Enfuvirtide is synthesized by making use of the fragments in solution phase.
...
The present invention relates to an improved process for the preparation of 7-chloro-4-piperazin-l-yl-quinoline of formula I, a key intermediate for the synthesis of Piperaquine or its pharmaceutically acceptable salts.
The present invention provides an improved process for the preparation of crystalline levomefolate calcium Form C.
Polymorphs of idelalisib are disclosed herein, including crystalline Form-M1 and Form-M2. Methods for the preparation thereof are also disclosed. Polymorphic forms disclosed herein may be useful for the preparation of oral dosage forms of idelalisib.
The present invention relates to an improved process for the preparation of pure compound of Formula-II, which is an intermediate in the preparation of Aliskiren and further conversion of compound of Formula-II into Aliskiren or its pharmaceutically acceptable salts.
The present invention relates to isolation of a novel solid form of Aliskiren intermediate of compound of Formula-Y and further conversion into Aliskiren or its pharmaceutically acceptable salts with improved yield and quality.
Abstract Process for the preparation of Aripiprazole Lauroxil
The present invention relates to a process for the purification of Aripirprazole lauroxil and further relates to process for the preparation of Aripirpazole Lauroxil.
The invention relates to oral film-coated tablet comprising febuxostat and one or more pharmaceutically acceptable excipients prepared by employing dry process, wherein the tablets are film-coated using dichloromethane or dichloromethane and isopropyl alcohol based film coating dispersion/ suspension to maintain feb...
The invention relates oral multi-particulate formulation comprising tenofovir and optionally one or more pharmaceutically acceptable excipient(s), wherein said multi-particulate(s) comprising tenofovir are prepared by employing extrusion-spheronization process and further said multi-particulate(s) comprising tenofov...
The present invention provides an improved process for the preparation of Raltegravir comprising, condensing free amine compound of formula III with an oxadiazole derivative of formula IV in presence of a dehydrating agent and a base in a suitable solvent. The present invention also relates to conversion of Raltegra...
“PROCESS FOR THE ENANTIOMERIC RESOLUTION OF APREMILAST INTERMEDIATES”
A process for the resolution of racemic 2-(3-ethoxy-4-methoxyphenyl)-1-(methylsulphonyl)-eth-2-ylamine using novel chiral salts is disclosed. An L-phenylalanine p-toluene-sulfonamide salt of (S)-2-(3-ethoxy-4-methoxyphenyl)-1-(methylsulphonyl)-et...
The present invention relates to a process for the preparation of amorphous saxagliptin hydrochloride, wherein the saxagliptin hydrochloride is dissolved in a solvent and evaporating to get amorphous saxagliptin hydrochloride. The present invention also relates to a preparation of a stable amorphous saxagliptin hy...
The present invention relates to an improved process for the preparation of Tenofovir Disoproxil and its pharmaceutically acceptable salts comprising the steps of: a) esterifying Tenofovir with chloromethyl isopropyl carbonate in presence of a base, phase transfer catalyst and optionally dehydrating agent, in a suit...
The present disclosure relates to amorphous and crystalline forms of 2-butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethyl amino)-,(2E)-, (2Z)-2-butenedioate (1:2) (afatinib dimaleate). The present disclosure also relates to process for the preparation of a...
The present invention related to a novel biocatalytic process for the preparation of (S) C1-C4 carboxylic acid, 1-(3-methoxy-phenyl)-ethyl ester of formula (II) and its fUrther conversion into (S)-Rivastigniine or phramceutically acceptable salts thereof
The present invention relates to an improved process for the preparation of Aliskiren and its pharmaceutically acceptable salts comprising reducing the compound of Formula-Z in presence of catalyst and ammonia. The present invention further relates to Aliskiren hemifumarate having diastereomeric impurity less than 0...
The present invention relates to one pot process for the preparation of Sumatriptan acid addition salts especially benzoate salt, wherein the process comprises reacting 4-Hydrazino-N-methyl Benzene methane Sulfonamide or its acid addition salt with 4-halo-1- hydroxy butane sulphonic acid or its alkaline salt in the ...
The present invention relates to an improved process for the preparation of Etoricoxib by reacting ketosulfone of formula-ll with vinamidinium salt of formula-Ill in the presence of an acid, followed by conversion to an acid addition salt and finally desaltifying to get Etoricoxib of formula-l.
...
The present invention relates to an improved process for the preparation Clopidogrel or pharmaceutically acceptable salts. The present invention also relates to Clopidogrel bisulphate polymorphic form I, having purity greater than 99.5%.
The present invention relates to a novel process for the preparation of Etravirine, comprises; condensing ethyl cyanoacetate with N-cyanophenylguanidine to obtain -OH compound of formula (II), which is further converted to a leaving group of formula (HI). Compound of formula (III) is optionally protected and bromina...
The invention relates to a process for preparing oral pharmaceutical compositions comprising aprepitant, graft copolymer of polyethylene glycol, polyvinylcaprolactam and polyvinyl acetate (Soluplus®) and optionally one or more pharmaceutically acceptable excipients. Specifically it relates to melt-extrusion process ...
The present disclosure provides processes for the preparation of amorphous daclatasvir dihydrochloride. The present disclosure also provides processes for the preparation of amorphous solid dispersion of daclatasvir dihydrochloride in at least one pharmaceutically acceptable carrier. Suitable pharmaceutically accept...
The present invention relates to an improved process for the preparation of intermediates of HMG-CoA reductase inhibitors of Formulae-IXa or IXb and further conversion to HMG-CoA reductase inhibitors and pharmaceutically acceptable salts thereof.
The present invention relates to improved process for the preparation of Vardenafil hydrochloride. Wherein 2-[2-ethoxy-phenyl]-5-methyl-7-propyl-3H-imidazo [5, 1-fJ [1, 2, 4] triazin-4-one of formula IV is reacted with chlorosulfonic acid and a chlorinating agent to get compound of formula III, which is reacted with...
“NOVEL SALT OF AMINE-PROTECTED (1S,2R,4S)-1,2-AMINO-N,N-DIMETHYLCYCLOHEXANE-4-CARBOXAMIDE)”
Disclosed are compounds and methods for the preparation of Edoxaban. In particular, a camphor sulfonate salt of an amine-protected [(1R,2S,5S)-1,2-amino-5-[(dimethylamino)carbonyl] cyclohexane, an intermediate that may be ...
The present invention relates to an improved process for the preparation of Etoricoxib. The present invention particularly related to Etoricoxib polymorphic Form-I by drying the mixture of polymorphs.
The present invention relates to novel processes for the preparation of compounds of Formula-II useful as intermediates in preparation of HMG-CoA reductase inhibitors, and further conversion of said intermediates to HMG-CoA reductase inhibitors. The process for the preparation of compounds of Formula-II comprises re...
The present invention relates to improved process for the preparation of Fingolimod hydrochloride.
PROCESS FOR THE PREPARATION OF LUMACAFTOR
The present disclosure relates to processes for the preparation of lumacaftor useful for treating a cystic fibrosis transmembrane conductance regulator (CFTR)-mediated disease such as cystic fibrosis. The present disclosure also provides intermediates useful in the prepar...
The invention relates to extended release oral tablet formulation comprising pramipexole, hydroxypropyl methylcellulose, pregelatinised maize starch (Starch 1500®) having tensile strength less than about 0.15 kN cm-2 at a solid fraction of 0.8 and one or more pharmaceutically acceptable excipient(s) prepared by dire...
PROCESS FOR THE PREPARATION OF ENZALUTAMIDE
A process for the preparation of enzalutamide. The disclosed process may be effectively implemented on an industrial scale. In some implementations, the following reaction step is employed in the production of enzalutamide.
PROCESS FOR THE PREPARATION OF REGORAFENIB
The present disclosure relates to process for the preparation of crystalline form-I of regorafenib that is viable on an industrial scale. The disclosed process permits the high yield production of high-purity crystalline form-I of regorafenib.
The present invention relates to stable, solid pharmaceutical composition comprising saxagliptin alone or in combination with metformin hydrochloride, wherein saxagliptin is stabilized by incorporating acidic stabilizer(s) and stability enhancing carrier(s). The invention also provides a process for preparation of s...
A ready to use, stable, concentrated, liquid composition of pemetrexed for intravenous injection, comprising pemetrexed disodium, hydroxypropyl-P-cyclodextrin and a pharmaceutically acceptable vehicle.
The present invention relates to an improved process for the preparation of Voriconazole comprising condensing 4-Chloro-6-ethyl-5-fluoro pyrimidine and 1 -(2,4-difluorophenyl)-2-(lH-l,2,4-triazol-l-yl)ethanone in presence of a diluted base and suitable solvent to give chloro Voriconazole and converted into its HC1 ...
PROCESS FOR THE PREPARATION OF BREXPIPRAZOLE
The present disclosure provides processes for the preparation of brexpiprazole or pharmaceutically acceptable salts thereof. The present disclosure also provides intermediates useful in the preparation of brexpiprazole.
ABSTRACT "Novel polymorphs of Vilazodone hydrochloride"
The present invention provides process for the preparation of Vilazodone HC1 comprising the steps of, a) dissolving Vilazodone free base in C1-4 carboxylic acid, b) adding hydrochloric acid source to the reaction mixture, and c) isolating Vilazodone hydrochlor...
Described herein are processes for the preparation of nepafenac and related intermediates, particularly wherein 2-aminobenzophenone is treated with a 2-(alkylthio)acetamide in the presence of sulfuryl chloride to afford a 2-(2-amino-3-benzoylphenyl)-2-(alkylthio)acetamide, which upon reduction affords nepafenac. Des...
PROCESSES FOR THE PREPARATION OF DABRAFENIB
A process for the preparation of dabrafenib and pharmaceutically acceptable salts thereof. The disclosed methods provide for an efficient and easily implemented method for the preparation of dabrafenib.
“Novel polymorph of Trametinib”
The present disclosure relates to Trametinib benzyl alcohol solvate, Trametinib ethyl acetate solvate and Trametinib anhydrous form. And also relates to process for the preparation of the same.
The invention relates to solid oral pharmaceutical compositions and its process for preparation, comprising rilpivirine and one or more pharmaceutically acceptable excipient(s), wherein the pharmaceutical composition is free of a wetting agent(s). More specifically, the invention relates to solid oral tablet and its...
DESCRIPTION COMPLETE NOT UPLOADED
ABSTRACT
“POLYMORPHS OF IXAZOMIB CITRATE AND PROCESSES FOR THE PREPARATION THEREOF”
The present disclosure provides amorphous ixazomib citrate and processes for the preparation thereof. Crystalline form M1, form M2, form M3, and form M4 of ixazomib citrate are also disclosed. The present disclosure also encompa...
"An improved process for the preparation of 1-Deoxynojirimycin, an intermediate of Miglitol"
The present invention relates to an improved process for the preparation of 1-Deoxynojirimycin, an intermediate in the preparation of Miglitol.
NOVEL FORMS OF LUMACAFTOR AND PROCESSES FOR THE PREPARATION THEREOF
The present disclosure provides amorphous lumacaftor, amorphous solid dispersions of lumacaftor, crystalline lumacaftor acetic acid solvate, crystalline lumacaftor ethyl acetate solvate, and processes for the preparation thereof. The lumacaftor for...
"An improved process for preparing Raltegravir"
The present invention relates to an improved process for preparing Raltegravir comprising hydrogenolysing benzyl protected compound of formula II in presence of hydrogen source and suitable solvent to give formula III, which is further converted into Raltegravir potas...
ABSTRACT
The present disclosure provides a process for the preparation of velpatasvir intermediates. The intermediates may be further converted to velpatasvir or pharmaceutically acceptable salts thereof.
[44] The present disclosure relates to processes for the preparation of dolutegravir or of its pharmaceutically acceptable salts. The present disclosure also provides intermediates useful in the synthesis of dolutegravir.
PROCESSES FOR THE PREPARATION OF AMORPHOUS OSIMERTINIB MESYLATE AND AMORPHOUS SOLID DISPERSIONS THEREOF
The present disclosure provides amorphous osimertinib mesylate, amorphous solid dispersions of osimertinib mesylate, and processes for the preparation thereof. Amorphous osimertinib mesylate and solid dispers...
This motor driving device includes a motor including a high speed drive coil and a low speed drive coil, a coil switching portion switching connection states of the high speed drive coil and the low speed drive coil of the motor, a power converter connected to the motor, and a single first case portion storing at le...
The invention relates to stable pharmaceutical composition and its process for preparation, comprising adefovir dipivoxil or its solvates and one or more pharmaceutically acceptable excipient(s) for oral administration, wherein the composition is devoid of any stabilizer and desiccant as a packaging aid. More specif...
The invention relates to a novel process for preparing ziprasidone pharmaceutical compositions. More particularly, the invention relates to a process for preparing ziprasidone pharmaceutical compositions by Hot-Melt extrusion process.
Nintedanib base polymorphic forms and processes for preparing the same. A process for the purification of nintedanib base is disclosed. An amorphous form of nintedanib and process for the preparation of the same are also disclosed. A solid dispersion of amorphous nintedanib with pharmaceutically acceptable excipient...
CRYSTALLINE CARFILZOMIB
The present disclosure provides crystalline carfilzomib form M1 and a process for the preparation thereof. Further disclosed are processes for the preparation of amorphous carfilzomib using crystalline form M1 as a starting material. The present disclosure also relates to an improved proces...
Present invention relates to process for the preparation of Montelukast comprising, reacting2-(2-(3(S)-(3-(2-(7-Chloro-2-quinolinyl)-ethenyl)phenyl)-3-methanesulfonylpropyl) phenyl)-2-propanol with l-(mercaptomethyl) cyclopropane acetic acid in presence of sodium alkoxide and a solvent such as N-methyl 2-pyrrolidone...
A wet granulated, tablet composition comprising docusate sodium, optionally in combination with sennosides and atleast one pharmaceuticaHy acceptable excipientCs), wherein said tablet composition is essentially prepared by employing non-aqueous granulating fluids
PROCESS FOR THE PREPARATION OF SOFOSBUVIR
Processes for the preparation of sofosbuvir or pharmaceutically acceptable salts thereof are disclosed herein. Intermediates useful in the synthesis of sofosbuvir are also disclosed.
The present disclosure relates to an improved process for the preparation of Mitiglinide with recovery of S-benzyl succinic acid, cis-octahydroisoindole from regioisomer.
TASTE MASKED CHEWABLE COMPOSITIONS OF RALTEGRAVIR
The invention relates to oral taste-masked compositions comprising raltegravir or its pharmaceutically acceptable salts and one or more pharmaceutically acceptable excipient(s), wherein said oral taste-masked compositions is prepared by using fluid bed processor.
...
The present invention relates to an improved process for the preparation of duloxetine hydrochloride. Wherein, (S)-3-methylamino-1-(2-thienyl) propan-1-ol is reacted with 1-fluoronaphthaline in the presence of a base and optionally using phase transfer catalyst in a solvent system consisting of dimethylsulfoxideand ...
The present invention relates to an improved process for the preparation of Fluticasone propionate.The present invention particularly related to the use of lithium halide reagent in the preparation of intermediate of formula III. The present invention also relates to the purification of fluticasone propionate.
...
The present invention relates to an improved process for the preparation of amorphous Vilazodone hydrochloride. The present invention further relates to process for the preparation of Vilazodone hydrochloride solid dispersion.
Methods of synthesizing pomalidomide are disclosed. Further, methods of purifying pomalidomide from a reaction mixture are also disclosed.
The present invention relates to an improved process for the preparation of pure crystalline form A of Oseltamivir phosphate or its intermediates thereof.
The present invention relates to an improved process for the preparation of Roflumilast. The present invention also relates to crystalline Form-I of Roflumilast.
The present invention relates to an improved process for the preparation of Febuxostat Form-K. The present invention also relates to a novel crystalline form Mi of Febuxostat.
Improved process for the preparation of Nitrofurantoin Macrocrystals
The present invention relates to an improved process for the preparation of Nitrofurantoin Macrocrystals by using Polar solvent.
The invention relates to a single layer monolithic tablet comprising sitagliptin, simvastatin and optionally one or more pharmaceutically acceptable excipient(s), wherein sitagliptin and simvastatin are present in two different physical forms or physically separated within the single layer monolithic tablet to overc...
The present disclosure relates to a process for purification of a tetrabenazine intermediate to remove specific impurities. The intermediate is then converted to tetrabenazine with improved yield and quality.
The invention relates to tablet comprising prasugrel, sugar alcohol(s) and optionally one or more pharmaceutically acceptable excipient(s) and the process for preparing the same. Tablet demonstrated lack of capping and sticking phenomenon, when sugar alcohol(s) having a particle size distribution in which D90 value ...
The present invention relates to an improved process for the preparation of Saxagliptin intermediate. The present invention also relates to a process for the preparation of Saxagliptin hydrochloride using this intermediate. The present invention is also relates to a novel intermediates of saxagliptin.
...
The present invention relates to a non-solvated crystalline Darunavir, process for its preparation and pharmaceutical composition comprising it. The present invention also relates to a process for the preparation of amorphous Darunavir from a non-solvated crystalline Darunavir.
The present invention relates to a process for preparing Linagliptin by purifying the intermediate compounds converting the purified intermediates into Linagliptin. The present invention also relates to the preparation of an amorphous Linagliptin.
The present invention relates to an improved process for the preparation of compound of Formula-II, which is an intermediate in the preparation of Aliskiren and further conversion of compound of Formula-II into Aliskiren or its pharmaceutically acceptable salts.
Formula-II wherein R1 and R2 are independently of one...
The invention relates to multi-particulate pharmaceutical compositions comprising orlistat, sugar alcohol(s) and one or more pharmaceutically acceptable excipients, prepared by extrusion-spheronization process, wherein said compositions are devoid of microcrystalline cellulose.
The present invention relates to an improved process for preparation of Rotigotine or an acid addition salt thereof. The present invention also relates to process for the preparation of crystalline Rotigotine hydrochloride and crystalline Rotigotine base. The present invention further relates to crystalline (-)-5-hy...
The present invention relates to novel process for the preparation of highly pure simvastatin. The process for the preparation of highly pure simvastatin comprises the reaction of ammonium salt of simvastatin with phosphoric acid and followed by treatment with base.
The present invention relates to a novel process for the preparation of Leuprolide or its pharmaceutically acceptable salts thereof by solid and solution phase peptide synthesis (Hybrid approach).
The present invention also relates to a process for the preparation of Leuprolide or its pharmaceutically acceptable ...
The present invention discloses high drug loaded solid oral dosage form of efavirenz for use in HIV therapy, having comparable in-vitro dissolution similar to that of SUSTIVA® tablets.
Also disclosed is a process for making the same.
The present invention relates to a novel process for the preparation of (3R, 3aS, 6aR)-hexahydrofuro [2, 3-b] furan-3-ol of formula I by reacting a compound of formula VII with the compound of formula R2-OH in the presence of haloginating agent to obtain a compound of formula VI and treating a compound of formula VI...
The present invention relates to an improved process for the preparation of Barnidipine or its pharmaceutically acceptable salt.
The present invention relates to an improved process for the preparation of compound of Formula-II, which is an intermediate in the preparation of HMG-CoA reductase inhibitors.
wherein X is hydrogen or hydroxy protecting group and R1 is carboxyl protecting group.
PROCESS FOR PREPARING SOLID ORAL FORMULATIONS COMPRISING LOW DOSE OF ENTECAVIR
ABSTRACT:
The invention relates to process for preparing solid oral pharmaceutical formulations comprising a low dose of entecavir and one or more pharmaceutical excipient(s), preferably in the form of compressed tablets having reproduc...
The present invention relates to an improved process for the preparation of 4-(4-Fluorophenyl)-5,6,7,8,9,10-hexahydro cyclooctane [b] pyridine-(lH)-ketone comprising the steps of hydrolyzing 4-Fluorobenzoyl acetonitrile in presence of an acid; reacting with Cyclooctanone; and isolating 4-(4-Fluorophenyl)-5,6,7,8,9,1...
The present invention relates to process for the preparation of Emtricitabine by reducing compound of formula II, protecting the -OH group with silyl group, deprotecting the silyl group and isolating Emtricitabine.
An improved process for the preparation of compound of Formula-XIII comprising the steps of
a) reacting the compound of Formula-II with magnesium in presence of Grignard reagents, and
b) condensing the obtained compound with compound of Formula-XII to get compound of Formula-XIII.
The invention relates to ready to use, ready to dilute stable liquid formulations comprising bendamustine or its pharmaceutically acceptable salts for parenteral administration and process for preparing the same. Specifically, the invention relates to stable liquid formulations for parenteral administration comprisi...
The invention relates to dispersible pharmaceutical compositions comprising deferasirox and one or more pharmaceutically acceptable excipients. More specifically, it relates to dispersible tablet comprising deferasirox, Cremophor® RH 40 and one or more pharmaceutically acceptable excipients, wherein the tablet is pr...
ABSTRACT
"STABLE AMORPHOUS LEVOMEFOLATE CALCIUM"
The present invention provides an improved process for the preparation of amorphous Levomefolate calcium. The present invention also provides stable Levomefolate calcium in amorphous form.
The invention relates to stable pharmaceutical composition comprising fluindione or its pharmaceutically acceptable salts, ascorbic acid and optionally one or more pharmaceutically acceptable excipient(s). More specifically, the invention relates to stable pharmaceutical composition in tablet form and its process fo...
The present invention relates to cobicistat intermediates, processes and further conversion to cobicistat with improved yield and quality.
The present invention relates to novel crystalline form of olanzapine pamoate and process for the preparation of crystalline olanzapine pamoate form-l, wherein olanzapine base is treated with pamoic acid in a solvent to get olanzapine pamoate salt, which is further suspended in an alcohol solvent, followed by stirri...
ABSTRACT "An improved process for preparing Lurasidone Hydrochloride"
The present invention relates to an improved process for preparation of trans-R,R-dimesylate comprising reducing the diacid of Formula IV followed by mesylation of formula V. The present invention further relates to preparation of Lurasidone HC1 ...
The present invention is process for the preparation of Clopidogrel bisulphate form 1 from different salts of clopidogrel.
The present invention relates to an improved process for enhancing the optical purity of chiral alcohols compounds. The chiral alcohols are used in the preparation of HIV reverse transcriptase inhibitor such as Efavirenz.
ABSTRACT
"Improved process for the preparation of L-monovaline esters of purine derivatives"
The present invention relates to an improved process for the preparation of pure mono protected L-valine ester of ganciclovir and its further conversion to Valganciclovir Hydrochloride. Further, the present invention relat...
"PROCESS FOR THE PREPARATION OF LIRAGLUTIDE" The present invention relates to an improved process for the synthesis of liraglutide or pharmaceutically acceptable salts by hybrid approach. The fragments are synthesized by solid phase synthesis approach and the liraglutide is synthesized by making use of the fragment...
PROCESS FOR THE PREPARATION OF LEDIPASVIR
Chemical synthetic methods useful for the synthesis of ledipasvir and pharmaceutically acceptable salts thereof are disclosed.
PROCESS FOR THE PREPARATION OF DACLATASVIR
The present disclosure provides a novel process for the preparation of daclatasvir or pharmaceutically acceptable salts thereof using novel intermediates.
PROCESS FOR THE PREPARATION OF APIXABAN
The present disclosure provides processes and intermediates for the preparation of apixaban.
An amorphous form of tenofovir alafenamide hemifumarate and process for the preparation of the same. A premix of amorphous tenofovir alafenamide hemifumarate with pharmaceutically acceptable excipients and process for the preparation of the same are also disclosed.
The present invention relates to an improved process for the preparation of Mirabegron. The present invention further relates to (R)-acetoxy-N-[2-(4-nitrophenyl)ethyl]-2-phenylacetamide , a novel intermediate in the preparation of Mirabegron.
IMPROVED PROCESS FOR THE PREPARATION OF MACITENTAN
The present invention relates to an improved process for the preparation of Macitentan.
The present invention relates to the process for the preparation of 3-amino-3-cyclobutylmethyl-2-hydroxypropionamide or an acid addition salt thereof and its further conversion into Boceprevir.
The present disclosure relates to crystalline forms of levomefolate calcium). The present disclosure also relates to a process for the preparation of crystalline forms of levomefolate calcium.
IMPROVED PROCESS FOR THE PREPARATION OF CHLORTHALIDONE
The present invention relates to methods for preparing chlorthalidone. In particular, the disclosed processes are feasible on an industrial scale and provide substantially pure chlorthalidone.
‘NOVEL CRYSTALLINE FORM OF DEUTETRABENAZINE’
Crystalline Form M1 of deutetrabenazine is provided along with methods of its preparation. Deutetrabenazine may be useful in the treatment of a VMAT2-mediated disease and thus crystalline Form M1 of deutetrabenazine may be incorporated into suitable dosage forms for admi...
“Co-crystal of Roxadustat”
The present invention relates to Co-crystal of Roxadustat with proline and its preparation thereof.
Sotagliflozin may be prepared using schemes and intermediates disclosed herein. Sotagliflozin may be incorporated into pharmaceutical dosage forms for treatment of diabetes.
ABSTRACT
“PROCESS FOR THE PREPARATION OF PURE PIBRENTASVIR”
The present disclosure relates to process for the preparation of pure Pibrentasvir.
The present invention provides polymorphic form M1, M2 and M3 of ozanimod. It also provides amorphous solid dispersions of ozanimod.
POLYMORPHIC FORMS OF VENETOCLAX
The present invention relates to crystalline forms of venetoclax and process for their preparation. The present invention also relates to process for preparation of amorphous venetoclax.
ABSTRACT
“APALUTAMIDE POLYMORPHS AND THEIR PREPARATION THEREOF”
The present invention discloses Novel polymorphs of Apalutamide and process for their preparation. The present invention further discloses processes for the preparation of amorphous and amorphous solid dispersion of Apalutamide.
...
ABSTRACT
“PROCESS FOR THE PREPARATION OF BEDAQUILINE FUMARATE”
The present disclosure relates to an improved process for the preparation of bedaquiline fumarate.
The present invention provides a novel process for preparing Ripasudil or its pharmaceutically acceptable salts using novel oxalate, camphor sulfonate, phosphate and fumarate salts of formula II, which are used as intermediates in the process for the preparation of Ripasudil or its pharmaceutically acceptable salts...
The present disclosure relates to a process for the preparation of amorphous form bictegravir sodium.
The present disclosure relates to crystalline forms of venetoclax and process for their preparation. The present disclosure also relates toprocess for preparation of amorphous venetoclax.
The present disclosure provides a novel polymorph of an intermediate useful in the preparation of palbociclib. The polymorph has enhanced properties that influence process ability of the intermediate and synthesis of palbociclib.
PROCESS FOR PREPARING STERILE ARIPIPRAZOLE FORMULATION
The invention provides a process for preparing a sterile suspension comprising aripiprazole. More particularly, the invention provides the process for preparing the sterile suspension comprising aripiprazole, wherein said process involves in-process moist-hea...
POLYMORPHIC FORMS OF SELEXIPAG
The present disclosure relates to crystalline forms of selexipag and their processes for preparation. The present disclosure also relates to an amorphous solid dispersion of selexipag and its processes for their preparation as well as premix of crystalline selexipag and their process....
POLYMORPHIC FORMS OF SOFOSBUVIR
The present disclosure provides novel crystalline sofosbuvir form-M3 and a process for the preparation of sofosbuvir form-M3. The crystalline sofosbuvir form-M3 disclosed herein may be useful in the formulation of pharmaceutical dosage forms.
The invention relates to stable liquid injectable pharmaceutical composition comprising thiotepa, PHARMASOLVE™ (N-methyl-2-pyrrolidone), and optionally one or more pharmaceutically acceptable excipients and processes for preparing the same.
The invention also relates to stable liquid injectable pharmaceutical com...
ABSTRACT
A process for the preparation of amorphous ibrutinib. A premix of amorphous ibrutinib with pharmaceutically acceptable excipients and process for the preparation thereof are also disclosed. An anisole solvate, an isopropyl acetate solvate, a xylene solvate, and a tert-butyl acetate solvate of ibrutinib a...
PROCESS FOR THE PREPARATION OF VENETOCLAX
The present disclosure provides novel synthetic process for the preparation of venetoclax. The disclosed processes involve the use of novel intermediates. Processes for the preparation of these intermediates are also disclosed as well as methods for the preparation of par...
The present disclosure provides solid dispersions of trisodium sacubitril valsartan. Such solid dispersions may be useful in the manufacture of pharmaceutical dosage forms.
An amorphous form of betrixaban maleate and process for the preparation of the same are disclosed. A solid dispersion of amorphous betrixaban maleate with pharmaceutically acceptable excipients and processes for the preparation of the same are also disclosed. Betrixaban base polymorphic forms and processes for pre...
“POLYMORPHIC FORMS OF BARICITINIB”
The present disclosure provides crystalline forms of baricitinib, crystalline forms of baricitinib hydrochloride, and processes for the preparation thereof.
“A PROCESS FOR BETRIXABAN HYDROCHLORIDE AND BETRIXABAN MALEATE SALT”
Disclosed herein is a process for the preparation of betrixaban hydrochloride and a process for the preparation of betrixaban maleate from betrixaban hydrochloride salt.
“CRYSTALLINE POLYMORPHS OF ABEMACICLIB”
The present disclosure provides novel polymorphs of abemaciclib, solid dispersions of abemaciclib with pharmaceutical excipients, and processes for the preparation thereof. The disclosure further provides methods for preparing crystalline abemaciclib form I, amorphous abema...
ABSTRACT
“PROCESS FOR THE PREPARATION OF CLOFAZIMINE”
The invention relates to process for the preparation of Clofazimine by reacting acetate salt of Imine compound of Formula II with an iso-propyl amine. It also provides a crystalline form of acetate salt of Imine compound of Formula II.
A process for the preparation of Osimertinib or their pharmaceutically acceptable salts and its intermediate preparation thereof
The present disclosure provides crystalline forms of bictegravir, amorphous bictegravir sodium, amorphous solid dispersion of bictegravir sodium with pharmaceutically acceptable carrier and processes for the preparation thereof.
The present invention provides, crystalline Form M1, Form M2 and Form M3 of Rucaparib (S)-camsylate salt. It also provides crystalline Form M1, Form M2, Form M3, Form M4 and Form M5 of Rucaparib and processes for the preparation of the same.
“Sonocrystallization of Azilsartan”
The present disclosure relates to sonocrystallization process for the preparation of Azilsartan having a lower particle size value.
The present invention relates to process for the preparation of Abametapir. The present invention further relates to Abametapir salts and their preparation thereof.
The present invention relates to a novel process for the preparation of Delamanid with or without isolation of intermediates.
The inventors of the present disclosure have developed processes for the preparation of amorphous brigatinib, amorphous solid dispersion of Brigatinib with pharmaceutically acceptable carriers.
The present invention relates to novel polymorphs of Ribociclib and it’s Succinate salt.
The present invention relates generally to pharmaceutically active compounds and more specifically to crystalline Form M1 of Avatrombopag, crystalline Form M2 of Avatrombopag, crystalline Form M3 of Avatrombopag , crystalline Form M4 of Avatrombopag, crystalline Form M5 of Avatrombopag, crystalline Form M1 of Avatro...
The present invention relates to a process for the preparation of voxilaprevir and its intermediates.
The present invention relates to novel salts of deutetrabenazine namely saccharinate monofumarate, hemifumarate, its polymorphs and its process for the preparation thereof.
The present invention provides pharmaceutically acceptable salts of Rucaparib selected from hydrochloride salt, succinate salt, fumarate salt, citrate salt and oxalate salt. It also provides crystalline form M1 and M2 of Rucaparib hydrochloride salt.
The present invention provides a novel 1:1 co-crystal of (rac)-tramadol hydrobromide-celecoxib and processes for the preparation of the same by reacting (rac)-tramadol with hydrobromic acid and celecoxib. It also provides crystalline form of (rac)-tramadol hydrobromide.
The present disclosure provides methods for purified Plecanatide by a two-step purification method, novel intermediates that may be used in the preparation of Plecanatide, and purified Plecanatide compositions.
The present disclosure relates to crystalline forms of Roxadustat Sodium and their preparation process thereof. The present invention further relates to process for the preparation of amorphous Roxadustat, Roxadustat morpholine salt and its preparation thereof.
The present invention relates to an improved process for the preparation of Pibrentasvir or its pharmaceutically acceptable salts.
Described is a process for the preparation of crystalline Form C of Vadadustat. Also described are Vadadustat co-crystals and processes for the preparation thereof.
The present invention relates to an improved process for the preparation of Abaloparatide or pharmaceutically acceptable salts.
The present invention provides an improved process for the preparation Upadacitinib by using novel intermediates. The present invention also provides processes for the preparation of novel intermediates of Upadacitinib.
The inventors of the present disclosure have developed salts of brigatinib and processes for the preparation thereof.
The present invention provides a solid dispersion of amorphous Larotrectinib sulfate and process for the preparation of the same.
The present invention provides an improved process for the preparation of Rucaparib or its pharmaceutically acceptable salts by the in-situ reductive amination of Formula-II.
The present invention provides co-crystal of sotagliflozin proline and its preparation thereof also process for the preparation of an amorphous sotagliflozin as well as an amorphous solid dispersion of sotagliflozin with pharmaceutically acceptable carriers and its preparation thereof.
Co-crystals of meloxicam co-formers can be prepared by co-crystallization from a polar solvent, such as aqueous dimethyl sulfoxide; or by slurry processes, such as with ethyl acetate. Such co-crystals have improved purities and are physically stable under storage for several months.
The present invention relates to an improved process for the preparation of Valbenazine tosylate. Further the present invention relates to crystalline acid addition salts of Valbenazine and their preparation thereof.
“Co-crystal of Roxadustat”
The present invention relates to Co-crystal of Roxadustat and its preparation thereof.
The present invention relates to novel crystalline form of Ribociclib Succinate and its preparation process.
The present invention relates to novel crystalline forms of Ribociclib Hemi Succinate and it’s preparation.
Aspects of the present application relates to novel crystalline form of Apalutamide, process for the preparation thereof and further process for the preparation of amorphous solid dispersion of Apalutamide.
The present invention relates to bictegravir salts, polymorphic forms of bictegravir salts and a process for the preparation thereof.
PROCESS FOR THE PREPARATION OF CABOTEGRAVIR
ABSTRACT
Processes for the preparation of cabotegravir and pharmaceutically acceptable salts utilizing alkenylamine are disclosed.
IMPROVED PROCESS FOR THE PREPARATION OF PURE FAVIPIRAVIR”
The present invention relates to an improved process for the preparation of pure Favipiravir using novel intermediate
A PROCESS FOR THE PREPARATION OF OZANIMOD INTERMEDIATE
The present invention provides a process for the preparation of (S)-1-hydroxy-2,3-dihydro-1H-indene-4-carbonitrile, which is key intermediate in the preparation of ozanimod by reacting 1-oxo-2,3-dihydro-1H-indene-4-carbonitrile with DIP chloride.
...
The inventors of the present disclosure have developed an improved process for the preparation of brigatinib and also a process for the preparation of crystalline brigatinib Form A.
POLYMORPHIC FORMS OF GLECAPREVIR
The present disclosure relates to novel crystalline and amorphous forms of Glecaprevir and
their preparation thereof.
ABSTRACT:
AN IMPROVED PROCESS FOR THE PREPARATION OF UPADACITINIB INTERMEDIATE.
The present invention provides an improved process for the preparation of upadacitinib of intermediate of formula II by reacting formula B with Grignard reagent in presence of an Iron catalyst.
CO-CRYSTAL OF FAVIPIRAVIR”
The present invention relates to Co-crystal of Favipiravir with 4-Hydroxybenzoic acid and its preparation thereof.
The present invention relates to a process for the preparation of amorphous Avatrombopag maleate, Avatrombopag maleate crystalline form B and form C.
The present invention relates to novel pharmaceutical composition comprising meloxicam for the treatment of acute pain, wherein the composition comprises at least a hydrophilic polymer and one or more alkalizing agents or combinations thereof.
Active agent combinations are provided for the treatment and/or prevention of COVID-19.
POLYMORPHIC FORMS OF OZANIMOD HYDROCHLORIDE
The present invention provides crystalline polymorphic Form M1, M2, M3, M4, M5 and M6 of Ozanimod hydrochloride. It also provides process for the preparation of the same.
(3S,4R)-3-ETHYL-4-(3H-IMIDAZO[L,2-A] PYRROLO[2,3-E] PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL) PYRROLIDINE- 1-CARBOXAMIDE CO-CRYSTALS.
The present invention provides a co-crystal of Upadacitinib-fumaric acid and a co-crystal of Upadacitinib-succinic acid, followed by processes for the preparation of the same.
...
“Improved process for the preparation of Iron complex”
“The present invention relates to an improved process for the preparation of Iron dextran & Sodium ferric gluconate, which is reproducible, easy to prepare on an industrial scale, and consistent in molecular weight range.
METHODS AND INTERMEDIATES FOR PREPARING RUCAPARIB
The present invention relates to a process for preparing rucaparib or pharmaceutically acceptable salts thereof. It also provides novel intermediates that may be converted into rucaparib or pharmaceutically acceptable salts thereof.
Disclosed is a process for the preparation of deutetrabenazine and intermediates useful in the preparation thereof. Disclosed are also process for making amorphous deutetrabenazine
The present invention provides an amorphous form of (rac)-tramadol. HCl-celecoxib (1:1) and a solid dispersion and processes for the preparation of the same.
The present invention relates to novel acid addition salts of Betrixaban selected from formic acid, cinnamic acid and salicylic acid and its process for the preparation thereof.
“ Improved process for the preparation of Ribociclib Succinate”
The present invention relates to an improved process for the preparation of Ribociclib intermediates and further conversion to Ribociclib or its salts.
The present invention relates to novel crystalline forms of Ribociclib Succinate and its preparation process.
The present disclosure relates to amorphous form of bedaquiline fumarate and process for its preparation thereof.
“IMPROVED PROCESS FOR THE PREPARATION OF ROXADUSTAT”
A synthetic route for the preparation of Roxadustat, or a pharmaceutically acceptable salt thereof. Each route involves several novel intermediates and avoids the use of column chromatography.
POLYMORPHIC FORMS OF CABOTEGRAVIR SODIUM
The present disclosure relates to amorphous cabotegravir sodium and a process for the preparation thereof.
“PROCESS FOR THE PREPARATION OF AMORPHOUS TENELIGLIPTIN 2.5 HYDROBROMIDE”
The present disclosure provides a process for preparation of amorphous Teneligliptin 2.5 hydrobromide. The present disclosure further provides process for preparation of crystalline form A and form C of Teneligliptin 2.0 hydrobromide.
...
The present invention provides novel intermediates of formula IV and formula VI, which are key intermediates in the process of Upadacitinib.
“CRYSTALLINE FORMS OF ROXADUSTAT”
The present invention relates to crystalline forms of Roxadustat and process for their preparation thereof.
A PROCESS FOR THE PREPARATION OF OZANIMOD OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS.
The present invention provides a process for resoluting an intermediate of formula II to give an amine intermediate of formula V, which is a key intermediate in the preparation of Ozanimod or its pharmaceutically acceptable salts.
...
A PROCESS FOR THE PREPARATION OF LAROTRECTINIB OR ITS SALTS.
The present invention provides a process for the preparation of Larotrectinib or its pharmaceutically acceptable salts with a key intermediate of Formula IV by using Formula IIa.
AN IMPROVED PROCESS FOR THE PREPARATION OF AMORPHOUS UPADACITINIB
The present invention provides an improved process for the preparation amorphous Upadacitinib by using upadacitinib organic acid addition salts such as oxalate and di-p-toluoyl tartarate salt.
The present invention relates to solid Ferumoxytol and its process for the preparation thereof.
PROCESS FOR THE PREPARATION OF PURE SALCAPROZATE SODIUM
The present invention relates to process for the preparation of pure Salcaprozate sodium free of color impurities.
ABSTRACT
Polymorphic forms of Sacubitril-Telmisartan (1:1)
The present invention provides polymorphic forms namely crystalline Form I, amorphous form and amorphous solid dispersions of Sacubitril-Telmisartan. It also provides process for the preparation of the same.
ABSTRACT
PROCESS FOR THE PREPARATION OF LIRAGLUTIDE
The present disclosure relates to a process for the preparation of liraglutide by fragment condensation in solution phase whereas the fragments are generated through the conventional solid phase synthesis and liquid phase synthesis. Both solid phase synthesis...
ABSTRACT
POLYMORPHIC FORMS OF BICTEGRAVIR SODIUM
The present disclosure relates to novel crystalline forms of bictegravir sodium and processes for their preparation.
Registered Trademarks
[Class : 5] Medicinal And Pharmaceutical Preparations For The Treatment Of Infections
[Class : 5] Medicinal And Pharmaceutical Preparations For The Treatment Of Cardiovascular Disorders
[Class : 5] Pharmaceutical / Medicinal Preparations For The Treatment Of Hiv/ Aids.
View +176 more Brands for Mylan Laboratories Limited.
Charges
12 April 2005
Andhra Bank
18 Crore
19 February 2007
Hdfc Bank Limited
45 Crore
09 July 2006
Abn Amro Bank
45 Crore
21 July 2009
Indusind Bank Ltd.
30 Crore
21 September 2007
Bank Of Nova Scotia
40 Crore
20 March 2009
The Bank Of Nova Scotia
40 Crore
15 January 2005
Hdfc Bank Limited
43 Crore
01 December 2003
Hdfc Bank Limited
26 Crore
08 January 2010
The Royal Bank Of Scotland N. V.
47 Crore
27 January 2011
Dbs Bank Ltd
48 Crore
28 January 2004
State Bank Of India
810 Crore
21 July 2009
Indusind Bank Ltd.
70 Crore
03 February 2010
The Hongkong And Shanghai Banking Corporation Limited
810 Crore
18 February 2004
The Royal Bank Of Scotland Nv
70 Crore
29 December 2003
The Bank Of Nova Scotia
100 Crore
23 June 2011
Dbs Bank Limited
48 Crore
27 November 2012
Yes Bank Limited
40 Crore
08 October 2012
Export - Import Bank Of India
150 Crore
18 December 2010
Central Bank Of India
237 Crore
24 October 2011
Axis Bank Limited
227 Crore
16 September 2010
Central Bank Of India
130 Crore
10 July 2012
Yes Bank Limited
60 Crore
20 June 2012
Axis Bank Limited
295 Crore
24 December 2011
Axis Bank Limited
95 Crore
24 October 2011
Axis Bank Limited
227 Crore
11 June 2013
Icici Bank Limited
170 Crore
18 July 2012
The Ratnakar Bank Limited
50 Crore
06 February 2004
Andhra Bank
17 Crore
16 February 2010
State Bank Of India
470 Crore
18 February 2003
Export - Import Bank Of India
10 Crore
13 March 2003
Export - Import Bank Of India
50 Lak
13 December 2001
Export - Import Bank Of India
12 Crore
22 February 2003
Export - Import Bank Of India
50 Lak
03 March 2004
Export-import Bank Of India
35 Lak
24 December 2007
Export-import Bnk Of India (exim Bank)
102 Crore
13 December 2001
Export - Import Bank Of India
12 Crore
02 December 2002
State Bank Of India
460 Crore
03 December 1997
State Bank Of India
10 Crore
28 March 1988
State Bank Of India
49 Lak
18 July 2000
State Bank Of India
49 Lak
28 March 1989
State Bank Of India
49 Lak
07 June 1995
State Bank Of India
4 Crore
21 July 2006
The Hongkong & Shanghai Banking Corporation Ltd.
45 Crore
21 October 2009
The Hongkong And Shanghai Banking Corporation Limited
86 Crore
11 September 2009
Yes Bank Limited
50 Crore
05 July 2011
Yes Bank Limited
40 Crore
11 March 2009
Ratnakar Bank Ltd
25 Crore
28 January 2004
Export-import Bank Of India
75 Crore
26 March 2005
Andhra Bank
8 Crore
26 May 2006
State Bank Of India
74 Crore
14 November 2002
Punjab National Bank
7 Crore
25 November 1988
Andhra Pradesh State Financial Corpaoration
2 Lak
11 February 1988
Ap State Financial Corporation
36 Lak
24 February 2003
Cooperative Centrale Raiffeisen - Boerenfeenbank B.a.
50 Lak
19 September 2003
Idbi Bank Ltd.
12 Crore
06 February 2004
Andhra Bank
0
01 December 2003
Hdfc Bank Limited
0
28 January 2004
Export-import Bank Of India
0
27 January 2011
Dbs Bank Ltd
0
11 June 2013
Icici Bank Limited
0
08 October 2012
Export - Import Bank Of India
0
19 February 2007
Hdfc Bank Limited
0
13 December 2001
Export - Import Bank Of India
0
16 February 2010
State Bank Of India
0
24 December 2011
Axis Bank Limited
0
07 June 1995
State Bank Of India
0
21 July 2009
Indusind Bank Ltd.
0
25 November 1988
Andhra Pradesh State Financial Corpaoration
0
24 October 2011
Axis Bank Limited
0
11 February 1988
Ap State Financial Corporation
0
05 July 2011
Yes Bank Limited
0
26 March 2005
Andhra Bank
0
15 January 2005
Hdfc Bank Limited
0
24 December 2007
Export-import Bnk Of India (exim Bank)
0
29 December 2003
The Bank Of Nova Scotia
0
12 April 2005
Andhra Bank
0
03 March 2004
Export-import Bank Of India
0
03 December 1997
State Bank Of India
0
18 July 2000
State Bank Of India
0
14 November 2002
Punjab National Bank
0
02 December 2002
State Bank Of India
0
18 February 2003
Export - Import Bank Of India
0
22 February 2003
Export - Import Bank Of India
0
24 February 2003
Cooperative Centrale Raiffeisen - Boerenfeenbank B.a.
0
13 March 2003
Export - Import Bank Of India
0
19 September 2003
Idbi Bank Ltd.
0
28 January 2004
State Bank Of India
0
28 March 1989
State Bank Of India
0
28 March 1988
State Bank Of India
0
13 December 2001
Export - Import Bank Of India
0
18 February 2004
The Royal Bank Of Scotland Nv
0
27 November 2012
Yes Bank Limited
0
18 July 2012
The Ratnakar Bank Limited
0
10 July 2012
Yes Bank Limited
0
20 June 2012
Axis Bank Limited
0
24 October 2011
Axis Bank Limited
0
23 June 2011
Dbs Bank Limited
0
18 December 2010
Central Bank Of India
0
16 September 2010
Central Bank Of India
0
03 February 2010
The Hongkong And Shanghai Banking Corporation Limited
0
08 January 2010
The Royal Bank Of Scotland N. V.
0
21 October 2009
The Hongkong And Shanghai Banking Corporation Limited
0
21 July 2009
Indusind Bank Ltd.
0
11 September 2009
Yes Bank Limited
0
20 March 2009
The Bank Of Nova Scotia
0
11 March 2009
Ratnakar Bank Ltd
0
21 September 2007
Bank Of Nova Scotia
0
09 July 2006
Abn Amro Bank
0
21 July 2006
The Hongkong & Shanghai Banking Corporation Ltd.
0
26 May 2006
State Bank Of India
0
06 February 2004
Andhra Bank
0
01 December 2003
Hdfc Bank Limited
0
28 January 2004
Export-import Bank Of India
0
27 January 2011
Dbs Bank Ltd
0
11 June 2013
Icici Bank Limited
0
08 October 2012
Export - Import Bank Of India
0
19 February 2007
Hdfc Bank Limited
0
13 December 2001
Export - Import Bank Of India
0
16 February 2010
State Bank Of India
0
24 December 2011
Axis Bank Limited
0
07 June 1995
State Bank Of India
0
21 July 2009
Indusind Bank Ltd.
0
25 November 1988
Andhra Pradesh State Financial Corpaoration
0
24 October 2011
Axis Bank Limited
0
11 February 1988
Ap State Financial Corporation
0
05 July 2011
Yes Bank Limited
0
26 March 2005
Andhra Bank
0
15 January 2005
Hdfc Bank Limited
0
24 December 2007
Export-import Bnk Of India (exim Bank)
0
29 December 2003
The Bank Of Nova Scotia
0
12 April 2005
Andhra Bank
0
03 March 2004
Export-import Bank Of India
0
03 December 1997
State Bank Of India
0
18 July 2000
State Bank Of India
0
14 November 2002
Punjab National Bank
0
02 December 2002
State Bank Of India
0
18 February 2003
Export - Import Bank Of India
0
22 February 2003
Export - Import Bank Of India
0
24 February 2003
Cooperative Centrale Raiffeisen - Boerenfeenbank B.a.
0
13 March 2003
Export - Import Bank Of India
0
19 September 2003
Idbi Bank Ltd.
0
28 January 2004
State Bank Of India
0
28 March 1989
State Bank Of India
0
28 March 1988
State Bank Of India
0
13 December 2001
Export - Import Bank Of India
0
18 February 2004
The Royal Bank Of Scotland Nv
0
27 November 2012
Yes Bank Limited
0
18 July 2012
The Ratnakar Bank Limited
0
10 July 2012
Yes Bank Limited
0
20 June 2012
Axis Bank Limited
0
24 October 2011
Axis Bank Limited
0
23 June 2011
Dbs Bank Limited
0
18 December 2010
Central Bank Of India
0
16 September 2010
Central Bank Of India
0
03 February 2010
The Hongkong And Shanghai Banking Corporation Limited
0
08 January 2010
The Royal Bank Of Scotland N. V.
0
21 October 2009
The Hongkong And Shanghai Banking Corporation Limited
0
21 July 2009
Indusind Bank Ltd.
0
11 September 2009
Yes Bank Limited
0
20 March 2009
The Bank Of Nova Scotia
0
11 March 2009
Ratnakar Bank Ltd
0
21 September 2007
Bank Of Nova Scotia
0
09 July 2006
Abn Amro Bank
0
21 July 2006
The Hongkong & Shanghai Banking Corporation Ltd.
0
26 May 2006
State Bank Of India
0
06 February 2004
Andhra Bank
0
01 December 2003
Hdfc Bank Limited
0
28 January 2004
Export-import Bank Of India
0
27 January 2011
Dbs Bank Ltd
0
11 June 2013
Icici Bank Limited
0
08 October 2012
Export - Import Bank Of India
0
19 February 2007
Hdfc Bank Limited
0
13 December 2001
Export - Import Bank Of India
0
16 February 2010
State Bank Of India
0
24 December 2011
Axis Bank Limited
0
07 June 1995
State Bank Of India
0
21 July 2009
Indusind Bank Ltd.
0
25 November 1988
Andhra Pradesh State Financial Corpaoration
0
24 October 2011
Axis Bank Limited
0
11 February 1988
Ap State Financial Corporation
0
05 July 2011
Yes Bank Limited
0
26 March 2005
Andhra Bank
0
15 January 2005
Hdfc Bank Limited
0
24 December 2007
Export-import Bnk Of India (exim Bank)
0
29 December 2003
The Bank Of Nova Scotia
0
12 April 2005
Andhra Bank
0
03 March 2004
Export-import Bank Of India
0
03 December 1997
State Bank Of India
0
18 July 2000
State Bank Of India
0
14 November 2002
Punjab National Bank
0
02 December 2002
State Bank Of India
0
18 February 2003
Export - Import Bank Of India
0
22 February 2003
Export - Import Bank Of India
0
24 February 2003
Cooperative Centrale Raiffeisen - Boerenfeenbank B.a.
0
13 March 2003
Export - Import Bank Of India
0
19 September 2003
Idbi Bank Ltd.
0
28 January 2004
State Bank Of India
0
28 March 1989
State Bank Of India
0
28 March 1988
State Bank Of India
0
13 December 2001
Export - Import Bank Of India
0
18 February 2004
The Royal Bank Of Scotland Nv
0
27 November 2012
Yes Bank Limited
0
18 July 2012
The Ratnakar Bank Limited
0
10 July 2012
Yes Bank Limited
0
20 June 2012
Axis Bank Limited
0
24 October 2011
Axis Bank Limited
0
23 June 2011
Dbs Bank Limited
0
18 December 2010
Central Bank Of India
0
16 September 2010
Central Bank Of India
0
03 February 2010
The Hongkong And Shanghai Banking Corporation Limited
0
08 January 2010
The Royal Bank Of Scotland N. V.
0
21 October 2009
The Hongkong And Shanghai Banking Corporation Limited
0
21 July 2009
Indusind Bank Ltd.
0
11 September 2009
Yes Bank Limited
0
20 March 2009
The Bank Of Nova Scotia
0
11 March 2009
Ratnakar Bank Ltd
0
21 September 2007
Bank Of Nova Scotia
0
09 July 2006
Abn Amro Bank
0
21 July 2006
The Hongkong & Shanghai Banking Corporation Ltd.
0
26 May 2006
State Bank Of India
0
Documents
Form INC-28-20082021
Optional Attachment-(2)-20082021
Copy of court order or NCLT or CLB or order by any other competent authority.-20082021
Optional Attachment-(1)-20082021
Form INC-28-29032021-signed
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-22122020
Form AOC-4(XBRL)-22122020_signed
Copy of MGT-8-10112020
List of share holders, debenture holders;-10112020
Form MGT-7-10112020_signed
Form PAS-6-05112020_signed
Form MSME FORM I-28102020_signed
Form MR-1-15102020_signed
Copy of shareholders resolution-15102020
Copy of letter of consent to act as Managing Director/ Whole time Director/Manager ; -15102020
Copy of board resolution-15102020
Form MGT-14-13102020_signed
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-13102020
Form PAS-6-27082020_signed
Form DPT-3-12082020-signed
Optional Attachment-(1)-30062020
Form MSME FORM I-28042020_signed
Form MGT-14-23042020_signed
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-23042020
Form MGT-14-22042020_signed
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-22042020
List of share holders, debenture holders;-25112019
Copy of MGT-8-25112019
Form MGT-7-25112019_signed
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-12112019
